← 홈

Antibody

712개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 712개
AntibodystaleM.D. Anderson Cancer CenterPhase 2

Relatlimab-Nivolumab FDC (BMS-986213, BMS-986213 (Relatlimab-Nivolumab FDC))

Melanoma (Skin) · Melanoma (Skin)

#MelanomaSkin#Antibody#Phase2#항체#면역항체+2
효능 ORR 61.9%임상시험 1상태 RECRUITING
AntibodystaleBristol-Myers SquibbPhase 3

BMS-986012+Nivolumab (BMS-986489, BMS-986489 (BMS-986012+Nivolumab))

Extensive-Stage Small Cell Lung Cancer · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleHighlight TherapeuticsPhase 2

pembrolizumab (Keytruda, BO-112 with pembrolizumab)

Colorectal Cancer; Gastric Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleBioXcel Therapeutics IncPhase 2

pembrolizumab (Keytruda, BXCL701 plus Pembrolizumab)

Prostate Cancer; Neuroendocrine Tumors · Prostate Cancer

#ProstateCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleYuan YuanPhase 2

Balstilmab (Balstilmab)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodyBiologicstaleRochePhase 1

aka Avastin or Rhu MAb VEGF (Bevacizumab, Bevacizumab (aka Avastin or Rhu MAb VEGF))

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

and approved biosimilars (Bevacizumab, Bevacizumab (and approved biosimilars))

Solid Tumor; Colorectal Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Bevacizumab, Bevacizumab (drug), Herceptin (drug), drug)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 73%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab + Capecitabine + Radiotherapy (Bevacizumab + Capecitabine + Radiotherapy)

Rectal Cancer · Rectal Cancer

#RectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed + Carboplatin (Bevacizumab + Pemetrexed + Carboplatin)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

Bevacizumab + blood samples (Bevacizumab + blood samples)

Colorectal Cancer; Metastasis · Colorectal Cancer

#ColorectalCancer#Antibody#Preclinical#항체#면역항체+3
효능 ORR 41.7%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab + modified FOLFIRINOX (Bevacizumab + modified FOLFIRINOX)

Mucinous Ovarian Cancer; Fallopian Tube Cancer · Mucinous Ovarian Cancer

#MucinousOvarianCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab Biosimilar HLX04 (Bevacizumab Biosimilar HLX04)

Non-Squamous Non-Small Cell Lung Cancer · Non-Squamous Non-Small Cell Lung Cancer

#Non-SquamousNon-SmallCellLungCan#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

Bevacizumab Combined With PD-1 Monoclonal Antibody (Bevacizumab Combined With PD-1 Monoclonal Antibody)

Colorectal Cancer · PD-1

#PD-1#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab Plus Capecitabine (Bevacizumab Plus Capecitabine)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab and Bortezomib (Bevacizumab and Bortezomib)

Renal Cell Cancer · Renal Cell Cancer

#RenalCellCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab and Erlotinib (Bevacizumab and Erlotinib)

Cancer · Cancer

#Cancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 24%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

Bevacizumab and Sunitinib (Bevacizumab and Sunitinib)

Metastatic Renal Cell Carcinoma; Kidney Cancer · Metastatic Renal Cell Carcinoma

#MetastaticRenalCellCarcinoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Bevacizumab and trastuzumab maintenance therapy)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE

10 / 36 페이지

← 이전다음 →